Intercept Pharmaceuticals

New York, United States Founded: 2002 • Age: 24 yrs Listed Acquired By Alfasigma
Developer of therapeutics to treat progressive non-viral liver diseases

About Intercept Pharmaceuticals

Intercept Pharmaceuticals is a Healthcare company based in New York (United States) founded in 2002 by Mark Pruzanski, and was acquired by Alfasigma in September 2023. Intercept Pharmaceuticals has raised $121 million across 5 funding rounds from investors including Orbimed, Alfasigma and Genextra. The company has 341 employees. Intercept Pharmaceuticals offers products and services including FXR Agonist. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is Intercept Pharmaceuticals, Inc. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.

Company details

Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.

  • Headquarters New York, United States
  • Employees 341
  • Founders Mark Pruzanski
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website interceptpharma.com
  • Social LinkedIn X
  • Acquired by Alfasigma (Sep 2023)
  • Legal Name Intercept Pharmaceuticals, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $285.71 M (USD)
    10
    as on Dec 31, 2022
  • Total Equity Funding
    $121M (USD)

    in 5 rounds

  • Latest Funding Round
    $500M (USD), Post-IPO

    Aug 2021

  • Investors
    Orbimed

    & 4 more

  • Employee Count
    341
  • Acquired by
    Alfasigma

    (Sep 2023)

Products & Services of Intercept Pharmaceuticals

Intercept Pharmaceuticals offers a comprehensive portfolio of products and services, including FXR Agonist.

FXR Agonist
Therapeutic Drug

Treatment for primary biliary cholangitis liver disease

Funding Insights of Intercept Pharmaceuticals

Intercept Pharmaceuticals has successfully raised a total of $121M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $121M
  • Total Rounds 5
  • Last Round Post-IPO — $500M
  • First Round $41M

    (May 2006)

  • Investors Count 4

All 5 funding rounds of Intercept Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2021$500MPost-IPO––
–
Sep 2012$30MSeries C–Orbimed
Jan 2010$25MSeries B––
Jul 2008$25MSeries B––
May 2006$41MSeries A––
Valuation history

5 investors in total: 5 institutional.

Investors in Intercept Pharmaceuticals

Intercept Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Alfasigma and Genextra.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
A holding company focused on life science investments is operated.
genextra.itMilan, Italy
Manages investments and risks to deliver consistent returns for institutional investors.
2001bamfunds.comChicago, United States
Buyouts are targeted through venture capital and private equity investments.
jafco.co.jpMinato City, Japan
Generic tablets, capsules, syrups, and injectables are manufactured.
2015alfasigma.comBologna, Italy
Premium access

Investor details for Intercept Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Intercept Pharmaceuticals

189 people are tracked at Intercept Pharmaceuticals (104 in leadership, 6 in board & advisors, 79 in team); the tracked headcount is 341.

NameRoleGroup
Mark Pruzanski
FounderLeadership
Anne Chiplin
Senior Director, Safety Evaluation And Risk ManagementLeadership
Amarita S Randhawa Pharmd
Executive Medical Director - Nash, Medical AffairsLeadership
Mary Erickson
Vice President Clinical Research Translational MedicineLeadership
Jaimee Reid Jd, Llm
Head Of Legal Compliance And Privacy OfficerLeadership
Caroline Fajolle
Executive Director, Human Resources - Commercial And Quality & Tech OpsLeadership
Veruska di Sena
SVP - Head Of US Medical AffairsLeadership
Gina Arrigo Wilson
Associate Director Of Key AccountsLeadership
David Swift
Executive Director, Market Access Strategic AccountsLeadership
Kimberly Jones
Associate Director, Training U.s. CommercialLeadership
Sangeeta Sawhney M.D.
Svp, Head Research And DevelopmentLeadership
Richard Johnson
Senior Vice President Head Of Human ResourcesLeadership
Rosa Rodriguez
Senior Manager - Office Of The CEOLeadership
Hernan Cortez
Head, U.s. Key Accounts, Gastroenterology And HepatologyLeadership
Sara Whipple
Vice President - Financial Planning & AnalysisLeadership
Doug Houser
Director, Strategic AccountsLeadership
Julia Pronina
Director, Financial Planning & AnalysisLeadership
Thomas Rosenberg
Senior Director Accounting - ControllerLeadership
Scott Kline
Head Of Benefits, Wellness, & EngagementLeadership
Sharon O. Ferrer
Senior Director, US Patient Services & Channel OperationsLeadership

169 more people are available in the full profile.

Premium access

Complete people profiles for Intercept Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Intercept Pharmaceuticals

5 dated milestones of Intercept Pharmaceuticals across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded Intercept Pharmaceuticals is founded.
  2. Funding First funding round of $41.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $500.0M.
  5. Exit Acquired by Alfasigma.

Competitors of Intercept Pharmaceuticals

Intercept Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ngmbio.com2007San Francisco, United States$358.87M225
Biologics are developed for cardio-metabolic and liver diseases.
nimbustx.com2009Cambridge, United States$685M81
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
altimmune.com1997Gaithersburg, United States$58M17
Vaccines for infectious diseases and solid tumors are developed.
Premium access

Detailed competitors of Intercept Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Intercept Pharmaceuticals

The website of Intercept Pharmaceuticals (interceptpharma.com) receives about 7.7K visits a month and ranks #2,460,968 among all websites worldwide, #3,376 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    7.7K

    ▼ 12.4% vs previous month

  • Unique visitors
    4K

    per month

  • Global rank
    #2,460,968

    among all websites

  • Category rank
    #3,376

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Intercept Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
conatuspharma.com
100%
1K#14,248,892View details
agios.com
100%
21.8K#1,284,134View details
genfit.com
94%
4.9K#3,666,893View details
merck.com
94%
656.8K#78,842View details
fiercebiotech.com
75%
858.3K#81,022View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 14 similar websites and full traffic analytics for Intercept Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 14 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Intercept Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Intercept Pharmaceuticals

Premium access

Complete news archive for Intercept Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Intercept Pharmaceuticals

Intercept Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.

Intercept Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.

Intercept Pharmaceuticals is a funded company, having raised a total of $121M across 5 funding rounds to date. The company's 1st funding round was a Series A of $41M, raised on May 2006.

Intercept Pharmaceuticals has 341 employees.

Annual revenue of Intercept Pharmaceuticals is $285.71M as on Dec 31, 2022.

Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.

Intercept Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.

Intercept Pharmaceuticals offers FXR Agonist.

Intercept Pharmaceuticals has 5 investors. Key investors include Orbimed, Alfasigma, Genextra, Balyasny Asset Management, and JAFCO Group.

Intercept Pharmaceuticals operates through Intercept Pharmaceuticals, Inc..

Yes. Intercept Pharmaceuticals was acquired by Alfasigma in September 2023.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available